|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
13 EC cell lines were profiled for their PI3K pathway and KRAS mutational and PTEN protein status and treated with one MEK- and two PI3K- targeted inhibitors alone and in combination.
|
29426295 |
2018 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.
|
24995579 |
2014 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endometrial cancers have high rates of phosphoinositide 3-kinase (PI3K) pathway alterations.
|
31714586 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
|
23674493 |
2013 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K/mammalian target of rapamycin (mTOR) pathway aberrations occur in 40% to 80% of endometrial cancer.
|
24651628 |
2014 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of the PI3K pathway is seen in more than 90% of FGFR2<sup>mutant</sup> endometrial cancers.
|
28119489 |
2017 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Alterations in the PI3K pathway are prevalent in endometrial cancer due to PIK3CA mutation and loss of PTEN.
|
24561032 |
2014 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alterations in the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway are common in endometrial carcinoma.
|
16949921 |
2006 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although molecular characterization has been reported to customize therapeutic strategies and thereby improve therapeutic outcomes in EC, none of the targeted agents investigated (antiangiogenic and mTOR/PI3K pathway inhibitor agents) have resulted in a change in clinical practice in HR-EC.
|
31176047 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blockage of PI3K/Akt cascade may become a potential and effective way to control endometrial carcinoma, especially in ER-negative cancers, which show no response to endocrinal therapy.
|
16567092 |
2006 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
|
19234438 |
2009 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deregulated signaling via the phosphatidylinositol 3-kinase (PI3K) pathway is common in many types of cancer, but its clinicopathological significance in endometrial cancer remains unclear.
|
17924977 |
2007 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Downregulation of PDCD4 induced by progesterone is mediated by the PI3K/AKT signaling pathway in human endometrial cancer cells.
|
31233196 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
E2 stimulated cell proliferation and induced GPR30 expression and PI3K/Akt pathway activation in endometrial cancer cells, Ishikawa cells, and HEC-1A cells, whereas the expression of ERs remained unchangeable.
|
23235274 |
2013 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression profiling of 22 genes involved in PI3K-AKT signaling pathway was analyzed in 38 endometrial carcinomas using TaqMan low-density array (TLDA) analysis.
|
20173732 |
2010 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Focusing on ARID1A, we integrated mutation profiles with functional proteomics in 222 endometrial cancer samples, demonstrating that ARID1A mutations frequently co-occur with mutations in the phosphatidylinositol 3-kinase (PI3K) pathway and are associated with PI3K pathway activation. siRNA knockdown in endometrial cancer cell lines increased AKT phosphorylation supporting ARID1A as a novel regulator of PI3K pathway activity.
|
23028188 |
2012 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, genetic studies evaluated the effect of inflammatory cytokines secreted by visceral adipocytes in the modulation of angiogenesis and signaling pathways such as PI3K/AKT/mTOR, that result altered in the pathogenesis of EC.
|
30338797 |
2018 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, HOTAIR activated the PI3K/Akt pathway to promote EC progression by suppressing PTEN <i>in vivo</i> Taking these results together, we revealed that high expression of HOTAIR promoted cell proliferation and inhibited apoptosis through activating the PI3K/Akt pathway via binding to PTEN, which might provide a prognostic marker and therapeutic target of EC.
|
31527078 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we identified that CCL18 derived from TAMs upregulated KIF5B expression to promote EMT via activating the PI3K/AKT/mTOR signaling pathway in endometrial cancer.
|
30779215 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIF1A, NF-kB and PI3K/mTOR might be potential treatment targets in aggressive endometrial cancers with presence of tumor necrosis.
|
26485755 |
2015 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.
|
23538402 |
2013 |
|
Endometrial Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of an endometrial cancer risk allele within a member of the PI3K/AKT signaling pathway, more commonly activated in tumors by somatic alterations, raises the possibility that well tolerated inhibitors targeting this pathway could be candidates for evaluation as chemopreventive agents in individuals at high risk of developing endometrial cancer.
|
27259051 |
2016 |
|
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, through western blot analysis, we found that inhibition of CLDN6 remarkably decreased p-AKT, p-PI3K, and mTOR expression level in EC HEC-1B cell line.
|
30319275 |
2018 |
|
Endometrial Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In breast, colon, and endometrial cancers in which the PI3K pathway is activated by a combination of mutant PIK3CA and alterations in Ras, ERBB2/3, or PTEN, signaling to downstream elements such as Akt was mediated exclusively by the p110alpha isoform, rather than a combination of different PI3K isoforms.
|
18829572 |
2008 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this narrative review, we summarize the role and significance of PI3K-AKT-mTOR (PAM) pathway in ovarian and endometrial cancers, providing the most recent and relevant literature on the topic and addressing options for targeting PAM along with future perspectives of drug development.
|
31752654 |
2019 |